This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study to Evaluate the Lipid Regulating Effects of TRIA-662

This study has been completed.
Information provided by (Responsible Party):
Cortria Corporation Identifier:
First received: September 23, 2008
Last updated: August 29, 2013
Last verified: August 2013
The purpose of this study is to determine the effectiveness and safety of TRIA-662 (also known as 1-MNA) in treating elevated triglyceride levels in patients not receiving lipid lowering treatment. This study will determine the effects of TRIA-662 on commonly measured blood fats that are known to be important in the prevention of vascular disease.

Condition Intervention Phase
Hyperlipidemia Drug: Low Dose TRIA-662 Drug: High Dose TRIA-662 Drug: Placebo for TRIA-662 Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multi-Center Study to Evaluate the Lipid Regulating Effects of TRIA-662

Further study details as provided by Cortria Corporation:

Primary Outcome Measures:
  • The primary efficacy parameter is the percent change in total serum Triglycerides from baseline to end of study [ Time Frame: Baseline to end of 12 weeks of active treatment ]

Secondary Outcome Measures:
  • The secondary efficacy parameters include the percent change in total cholesterol (TC), its major lipoprotein sub-fractions and the effects on inflammatory markers [ Time Frame: From baseline to the end of 12 weeks of active treatment ]

Enrollment: 211
Study Start Date: September 2007
Study Completion Date: December 2008
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Low Dose TRIA-662
Drug: Low Dose TRIA-662
One Capsule 3 times a day
Other Name: 1-MNA
Active Comparator: 2
High Dose TRIA-662
Drug: High Dose TRIA-662
3 Capsules 3 times daily
Other Name: 1-MNA
Placebo Comparator: 3
Matching Placebo for TRIA-662
Drug: Placebo for TRIA-662
Matching Placebo for TRIA-662 taken 3 times a day
Other Name: Placebo

Detailed Description:
This is a randomized, double-blind, placebo-controlled, dose-ranging, multi-center study. Following a 6-8 week placebo and dietary-controlled baseline period, approximately 195 men and women with either hypertriglyceridemia or mixed hyperlipidemia with serum triglycerides (TG) > 200 mg/dl (2.26 mmol/l) will be randomized to receive either placebo, 30 mg TRIA-662 or 90 mg TRIA-662 three times daily for twelve weeks. Lipid and ancillary exploratory parameters will be evaluated at screening, during the baseline period, upon randomisation and throughout the 12-week active treatment period.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients at least 18 years of age at the time of informed consent (women of childbearing potential must be practicing adequate contraception)
  • Patients with mean serum TG > 200 mg/dl (2.26 mmol/l) and < 700 mg/dl (7.91 mmol/l) as measured at 2 sequential visits during the dietary controlled baseline period (Visits 2 and 3 or Visits 3 and 3a) and having lower level within 25% of upper level (higher value minus lower value)/higher value < 0.25)
  • Patients willing and able to sign an informed consent form and follow the protocol

Exclusion Criteria:

  • Patients who are pregnant or nursing
  • Patients with evidence of hepatic dysfunction [alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 1.5 times the upper limit of normal (ULN), bilirubin greater than 1.5 times ULN, or cirrhosis] or renal dysfunction (serum creatinine greater than 140 μmol/l, or nephrotic syndrome) as measured during the baseline phase
  • Patients with uncontrolled diabetes mellitus (fasting glucose level above 11 mmol/l or HbA1C above 10%) as measured during the baseline phase
  • Patients with hypothyroidism that is not treated or not stable for at least 6 months prior to study entry
  • Patients with uncontrolled hypertension (systolic blood pressure above 160 mm Hg and/or diastolic blood pressure above 110 mm Hg)
  • Patients with systolic blood pressure above 140 mm Hg AND three or more of the following cardiovascular risk factors:
  • Current cigarette smoker
  • HDL-C < 40 mg/dL (1.04 mmol/L)
  • Coronary heart disease in male first degree relative < 55 years of age
  • Coronary heart disease in female first degree relative < 65 years of age
  • Male age 45 years or older
  • Female age 55 years or older
  • Patients with known hyperuricemia or with a history of gout
  • Patients with an active peptic ulcer
  • Patients with known coronary artery disease, cerebrovascular disease or peripheral arterial disease that has previously required percutaneous coronary intervention or surgical intervention
  • Patients with known intolerance or allergy to niacin
  • Patients consuming more than 10 alcoholic drinks per week
  • Patients with a history of drug abuse
  • Patients receiving any lipid modifying agent within 4 weeks of entry into the baseline period
  • Patients participating in another clinical trial within 30 days of entry into the baseline period
  • Patients considered to be non-compliant to study medication (< 80% study medication) or diet during the placebo-baseline phase
  • Patients for whom the investigator determines that the study would not be appropriate
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00758303

Sponsors and Collaborators
Cortria Corporation
Principal Investigator: Jean C Tardif, M.D. Montreal Heart Center
  More Information

Additional Information:
Responsible Party: Cortria Corporation Identifier: NCT00758303     History of Changes
Other Study ID Numbers: Cortria-001
Study First Received: September 23, 2008
Last Updated: August 29, 2013

Keywords provided by Cortria Corporation:

Additional relevant MeSH terms:
Lipid Metabolism Disorders
Metabolic Diseases processed this record on August 16, 2017